Zhenglan Huang
Overview
Explore the profile of Zhenglan Huang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
282
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
He W, Liu S, Wei W, Qin R, Tan J, Tang J, et al.
Am J Cancer Res
. 2024 Jul;
14(6):2770-2789.
PMID: 39005688
Chronic myeloid leukemia (CML) is a common hematopoietic malignancy in adults. Great progress has been made in CML therapy with imatinib. However, resistance to imatinib may occur during treatment. BCR::ABL1...
2.
Zheng R, Wei W, Liu S, Zeng D, Yang Z, Tang J, et al.
Cell Commun Signal
. 2024 Jun;
22(1):314.
PMID: 38849885
Background: Abnormally expressed BCR/ABL protein serves as the basis for the development of chronic myeloid leukaemia (CML). The F-actin binding domain (FABD), which is a crucial region of the BCR/ABL...
3.
Qin R, Wang T, He W, Wei W, Liu S, Gao M, et al.
Cell Commun Signal
. 2023 Feb;
21(1):27.
PMID: 36721266
Background: The Philadelphia chromosome encodes the BCR-ABL fusion protein, which has two primary subtypes, P210 and P190. P210 and P190 cause Philadelphia-positive chronic myeloid leukemia (Ph+ CML) and Philadelphia-positive acute...
4.
Du Z, Huang Z, Chen X, Jiang G, Peng Y, Feng W, et al.
Exp Hematol Oncol
. 2022 Jun;
11(1):36.
PMID: 35672796
Background: Tyrosine kinase inhibitors have achieved quite spectacular advances in the treatment of chronic myeloid leukemia (CML), but disease progression and drug resistance that related to the T315I mutation, remain...
5.
Zeng D, Gao M, Zheng R, Qin R, He W, Liu S, et al.
Exp Hematol Oncol
. 2022 May;
11(1):33.
PMID: 35624462
Background: With the widespread clinical application of tyrosine kinase inhibitors (TKIs), an increasing number of chronic myeloid leukaemia (CML) patients have developed resistance or intolerance to TKIs. BCR/ABL is the...
6.
Zu B, Shi Y, Xu M, You G, Huang Z, Gao M, et al.
J Exp Clin Cancer Res
. 2022 Feb;
41(1):57.
PMID: 35139870
No abstract available.
7.
Dai H, Wang J, Huang Z, Zhang H, Wang X, Li Q, et al.
Technol Cancer Res Treat
. 2021 Nov;
20:15330338211052150.
PMID: 34723728
Resistance to tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia (CML) remains a problem in clinical treatment, and the mechanism has not been fully clarified. Autophagy can protect...
8.
Li Q, Huang Z, Peng Y, Wang X, Jiang G, Wang T, et al.
Front Oncol
. 2021 Sep;
11:698410.
PMID: 34504783
Abnormal subcellular localization of proteins is an important cause of tumorigenesis and drug resistance. Chromosome region maintenance 1 (CRM1), the nuclear export regulator of most proteins, has been confirmed to...
9.
Jiang G, Huang Z, Yuan Y, Tao K, Feng W
J Hematol Oncol
. 2021 Sep;
14(1):139.
PMID: 34488814
Background: The pathogenesis of chronic myeloid leukemia (CML) is the formation of the BCR/ABL protein, which is encoded by the bcr/abl fusion gene, possessing abnormal tyrosine kinase activity. Despite the...
10.
Tan Y, Huang Z, Wang X, Dai H, Jiang G, Feng W
Bioengineered
. 2021 Aug;
12(1):4816-4827.
PMID: 34346842
The fusion gene plays a crucial role in the leukemogenesis of chronic myeloid leukemia (CML). The BCR-ABL oncoprotein encoded by this fusion gene has been extensively studied. However, research on...